UA138236U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes clinical examination, radiography. Additionally, polymorphism of methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), thrombomodulin, folic acid, cartilaginous oligomeric matrix protein (6) ) and with a homozygous carrier of 677-TT, 786-CC and thrombomodulin levels> 5 ng / ml, folic acid <6 ng / ml, COMP> 595 ng / ml, PSA> 6 mg / l, IL-6> 10 ng / l predict the development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. It is prescribed and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The set task is solved by the fact that, in addition to clinical examination and radiography, polymorphism of methylenetetrahydrofolate reductase genes (MTNEV) is determined in the patient's blood serum

Сб77Т), nitric oxide synthase (eMOB5 17860), the content of thrombomodulin, folic acid, cartilage oligomeric matrix protein (COMP), C-reactive protein (CRP), interleukin 6 (IL-6). With homozygous carrier 677-TT, 786-SS, levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, SOMR "595 ng/ml, PSA "6 mg/l, IL-6 "10 ng/l predict development of osteoarthritis.

Application of the method. During hospitalization, the patient is examined, x-rays are taken, the polymorphism of MTNEV C677T, eMmo5 T786C genes is determined, the content of thrombomodulin, folic acid, SOMP, SRP, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-1t, 786-

SS, levels of thrombomodulin "5 ng/ml, folic acid "b ng/ml, SMP "595 ng/ml, SRP "6 mg/l,

IL-6 210 ng/l predict the development of osteoarthritis.

A specific example of using the method.

Patient 0O., 65 years old, was hospitalized due to pain in the left hip joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEV C677T and emo5 17860 genes were determined in blood serum. The content of thrombomodulin, folic acid, SOMP, SRP, and IL-6 was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, the levels of thrombomodulin - 15 ng/ml, folic acid -3.2 ng/ml, COMP

Zo - 125 ng/ml, SRP - 19 mg/l, IL-6 - 24 ng/l. The development of osteoarthritis was diagnosed. After 11 months, X-rays showed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination, radiography, which is distinguished by the fact that in the patient's blood serum polymorphisms of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (EMO5 1786С), the content of thrombomodulin, folic acid, cartilage oligomeric are additionally determined matrix protein (COMP), C-reactive protein (CRP), interleukin 6 (IL-6) and with homozygous carrier 677-TT, 786-SS and levels of thrombomodulin "5 ng/ml, folic acid "6 ng/ml, COMP »595 ng/ml, SRP »b mg/l, IL-6 210 ng/l predict the development of osteoarthritis.